AstraZeneca To Buy CinCor Pharma In Up To $1.8 Bln Deal – Quick Facts
British drug major AstraZeneca Plc. (AZN.L,AZN) Monday said it has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CINC), a US-based clinical-stage biopharmaceutical company. The upfront cash portion of the deal represents a transaction value of around $1.3 billion. On a combined basis, including the upfront and maximum potential contingent value payments, if achieved, the transaction value would […]
Read more